A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group.
作者:
主题词
成年人(Adult);老年人(Aged);老年人, 80以上(Aged, 80 and over);厌食(Anorexia);抗肿瘤药(Antineoplastic Agents);食欲(Appetite);双盲法(Double-Blind Method);女(雌)性(Female);基因型(Genotype);人类(Humans);免疫球蛋白G(Immunoglobulin G);免疫因子类(Immunologic Factors);男(雄)性(Male);中年人(Middle Aged);肿瘤(Neoplasms);姑息疗法(Palliative Care);生活质量(Quality of Life);受体, 肿瘤坏死因子(Receptors, Tumor Necrosis Factor);存活率分析(Survival Analysis);治疗结果(Treatment Outcome);肿瘤坏死因子α(Tumor Necrosis Factor-alpha);体重增长(Weight Gain);体重减轻(Weight Loss)
DOI
10.1002/cncr.22944
PMID
17674351
发布时间
2022-03-17
- 浏览16

Cancer
1396-403页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文